Navigation Links
MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
Date:6/9/2008


NEW YORK, June 9 /PRNewswire/ --

SATELLITE FEED:

Monday, June 9th, 2008

1:00 PM - 1:15 PM ET

Galaxy 26

Transponder 24

C-Band

Downlink Freq: 4180 H

NEWS: LARGE, LONG-TERM VETERANS AFFAIRS DIABETES TRIAL (VADT) REVEALS

IMPORTANT CARDIOVASCULAR SAFETY NEWS ON AVANDIA

FORMAT: B-roll and Sound bites

ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2, contact information and more available at http://www.prnewswire.com/broadcast/33475/press.html

STORY SUMMARY:

At the 68th Scientific Sessions of the American Diabetes Association in San Francisco, CA, several studies were presented evaluating the impact of blood sugar control to reduce diabetes-related complications in patients.

VADT (Veterans Affairs Diabetes Trial), a large, long-term and independent outcomes study, evaluated whether intensive versus standard blood sugar control can reduce the incidence of major cardiovascular (CV) events associated with diabetes including heart attack, congestive heart failure and CV death.

According to news announced by the ADA, AVANDIA(R) (rosiglitazone maleate) was used in a majority of patients in the study and was not associated with increased deaths. These data are consistent with results from other long-term studies with AVANDIA.

The primary result of VADT did not show that intensive blood sugar control (HbA1c levels below 7%) had a statistically significant effect on reducing major CV events associated with diabetes. However, it was found that there was a favorable trend in reducing all CV events, except CV death, among the patients in the intensive arm. While the VADT did not meet its primary endpoint, it is critical that these results do not detract from what is already known about the benefits of long-term blood sugar control on other serious and potentially
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
9. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
10. Discovering How Video Games Can Motivate Healthy Behaviors: More than $2 Million Awarded to 12 Research Teams Across U.S.
11. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Survivors of childhood cancer less likely to marry 10291 1Survivors of childhood cancer less likely to marry 10291 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 1HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 2HealthCare Partners IPA Dr Richard Merkin CEO Recognize Seniors Taking Their Healthcare Concerns Directly to Lawmakers in Washington DC 5314 3Statewide Drug Card Program Launching 59108 1